The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Glioblastoma Multiforme Treatment Market Research Report 2025
Synopsis
Glioblastoma multiforme (GBM) is a fast-growing type of tumour of the brain or spinal cord. It is the most common type of primary malignant brain tumour in adults.
The global Glioblastoma Multiforme Treatment market was valued at US$ 548.3 million in 2023 and is anticipated to reach US$ 996.4 million by 2030, witnessing a CAGR of 8.8% during the forecast period 2024-2030.
GBMs almost never spread outside of the brain, spine or central nervous system to other parts of the body. They are very challenging to treat because of their complex nature, which is why a great deal of research in the UK and around the world is focused on this tumour type.
This report aims to provide a comprehensive presentation of the global market for Glioblastoma Multiforme Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glioblastoma Multiforme Treatment.
Report Scope
The Glioblastoma Multiforme Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glioblastoma Multiforme Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glioblastoma Multiforme Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Merck
Teva
AbbVie, Inc
Bristol-Myers Squibb
Sun Pharmaceutical
Arbor Pharmaceuticals
Segment by Type
Bevacizumab (Avastin)
Carmustine (BiCNU)
Temozolomide (Temodar and Temodal and Temcad)
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glioblastoma Multiforme Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Glioblastoma multiforme (GBM) is a fast-growing type of tumour of the brain or spinal cord. It is the most common type of primary malignant brain tumour in adults.
The global Glioblastoma Multiforme Treatment market was valued at US$ 548.3 million in 2023 and is anticipated to reach US$ 996.4 million by 2030, witnessing a CAGR of 8.8% during the forecast period 2024-2030.
GBMs almost never spread outside of the brain, spine or central nervous system to other parts of the body. They are very challenging to treat because of their complex nature, which is why a great deal of research in the UK and around the world is focused on this tumour type.
This report aims to provide a comprehensive presentation of the global market for Glioblastoma Multiforme Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glioblastoma Multiforme Treatment.
Report Scope
The Glioblastoma Multiforme Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Glioblastoma Multiforme Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glioblastoma Multiforme Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Merck
Teva
AbbVie, Inc
Bristol-Myers Squibb
Sun Pharmaceutical
Arbor Pharmaceuticals
Segment by Type
Bevacizumab (Avastin)
Carmustine (BiCNU)
Temozolomide (Temodar and Temodal and Temcad)
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glioblastoma Multiforme Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glioblastoma Multiforme Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Bevacizumab (Avastin)
1.2.3 Carmustine (BiCNU)
1.2.4 Temozolomide (Temodar and Temodal and Temcad)
1.3 Market by Application
1.3.1 Global Glioblastoma Multiforme Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Glioblastoma Multiforme Treatment Market Perspective (2019-2030)
2.2 Glioblastoma Multiforme Treatment Growth Trends by Region
2.2.1 Global Glioblastoma Multiforme Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Glioblastoma Multiforme Treatment Historic Market Size by Region (2019-2024)
2.2.3 Glioblastoma Multiforme Treatment Forecasted Market Size by Region (2025-2030)
2.3 Glioblastoma Multiforme Treatment Market Dynamics
2.3.1 Glioblastoma Multiforme Treatment Industry Trends
2.3.2 Glioblastoma Multiforme Treatment Market Drivers
2.3.3 Glioblastoma Multiforme Treatment Market Challenges
2.3.4 Glioblastoma Multiforme Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glioblastoma Multiforme Treatment Players by Revenue
3.1.1 Global Top Glioblastoma Multiforme Treatment Players by Revenue (2019-2024)
3.1.2 Global Glioblastoma Multiforme Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Glioblastoma Multiforme Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Glioblastoma Multiforme Treatment Revenue
3.4 Global Glioblastoma Multiforme Treatment Market Concentration Ratio
3.4.1 Global Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme Treatment Revenue in 2023
3.5 Glioblastoma Multiforme Treatment Key Players Head office and Area Served
3.6 Key Players Glioblastoma Multiforme Treatment Product Solution and Service
3.7 Date of Enter into Glioblastoma Multiforme Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Glioblastoma Multiforme Treatment Breakdown Data by Type
4.1 Global Glioblastoma Multiforme Treatment Historic Market Size by Type (2019-2024)
4.2 Global Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2025-2030)
5 Glioblastoma Multiforme Treatment Breakdown Data by Application
5.1 Global Glioblastoma Multiforme Treatment Historic Market Size by Application (2019-2024)
5.2 Global Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Glioblastoma Multiforme Treatment Market Size (2019-2030)
6.2 North America Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
6.4 North America Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Glioblastoma Multiforme Treatment Market Size (2019-2030)
7.2 Europe Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
7.4 Europe Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Glioblastoma Multiforme Treatment Market Size (2019-2030)
8.2 Asia-Pacific Glioblastoma Multiforme Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Glioblastoma Multiforme Treatment Market Size (2019-2030)
9.2 Latin America Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
9.4 Latin America Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glioblastoma Multiforme Treatment Market Size (2019-2030)
10.2 Middle East & Africa Glioblastoma Multiforme Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Glioblastoma Multiforme Treatment Introduction
11.1.4 Roche Revenue in Glioblastoma Multiforme Treatment Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Glioblastoma Multiforme Treatment Introduction
11.2.4 Merck Revenue in Glioblastoma Multiforme Treatment Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Glioblastoma Multiforme Treatment Introduction
11.3.4 Teva Revenue in Glioblastoma Multiforme Treatment Business (2019-2024)
11.3.5 Teva Recent Development
11.4 AbbVie, Inc
11.4.1 AbbVie, Inc Company Detail
11.4.2 AbbVie, Inc Business Overview
11.4.3 AbbVie, Inc Glioblastoma Multiforme Treatment Introduction
11.4.4 AbbVie, Inc Revenue in Glioblastoma Multiforme Treatment Business (2019-2024)
11.4.5 AbbVie, Inc Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Glioblastoma Multiforme Treatment Introduction
11.5.4 Bristol-Myers Squibb Revenue in Glioblastoma Multiforme Treatment Business (2019-2024)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Sun Pharmaceutical
11.6.1 Sun Pharmaceutical Company Detail
11.6.2 Sun Pharmaceutical Business Overview
11.6.3 Sun Pharmaceutical Glioblastoma Multiforme Treatment Introduction
11.6.4 Sun Pharmaceutical Revenue in Glioblastoma Multiforme Treatment Business (2019-2024)
11.6.5 Sun Pharmaceutical Recent Development
11.7 Arbor Pharmaceuticals
11.7.1 Arbor Pharmaceuticals Company Detail
11.7.2 Arbor Pharmaceuticals Business Overview
11.7.3 Arbor Pharmaceuticals Glioblastoma Multiforme Treatment Introduction
11.7.4 Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme Treatment Business (2019-2024)
11.7.5 Arbor Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Glioblastoma Multiforme Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Bevacizumab (Avastin)
Table 3. Key Players of Carmustine (BiCNU)
Table 4. Key Players of Temozolomide (Temodar and Temodal and Temcad)
Table 5. Global Glioblastoma Multiforme Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Glioblastoma Multiforme Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Glioblastoma Multiforme Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Glioblastoma Multiforme Treatment Market Share by Region (2019-2024)
Table 9. Global Glioblastoma Multiforme Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Glioblastoma Multiforme Treatment Market Share by Region (2025-2030)
Table 11. Glioblastoma Multiforme Treatment Market Trends
Table 12. Glioblastoma Multiforme Treatment Market Drivers
Table 13. Glioblastoma Multiforme Treatment Market Challenges
Table 14. Glioblastoma Multiforme Treatment Market Restraints
Table 15. Global Glioblastoma Multiforme Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Glioblastoma Multiforme Treatment Market Share by Players (2019-2024)
Table 17. Global Top Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment as of 2023)
Table 18. Ranking of Global Top Glioblastoma Multiforme Treatment Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Glioblastoma Multiforme Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Glioblastoma Multiforme Treatment Product Solution and Service
Table 22. Date of Enter into Glioblastoma Multiforme Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Glioblastoma Multiforme Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Glioblastoma Multiforme Treatment Revenue Market Share by Type (2019-2024)
Table 26. Global Glioblastoma Multiforme Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Glioblastoma Multiforme Treatment Revenue Market Share by Type (2025-2030)
Table 28. Global Glioblastoma Multiforme Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Glioblastoma Multiforme Treatment Revenue Market Share by Application (2019-2024)
Table 30. Global Glioblastoma Multiforme Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Glioblastoma Multiforme Treatment Revenue Market Share by Application (2025-2030)
Table 32. North America Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Glioblastoma Multiforme Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Glioblastoma Multiforme Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Glioblastoma Multiforme Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Glioblastoma Multiforme Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Glioblastoma Multiforme Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Glioblastoma Multiforme Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Glioblastoma Multiforme Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Glioblastoma Multiforme Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Glioblastoma Multiforme Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Glioblastoma Multiforme Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 47. Roche Company Detail
Table 48. Roche Business Overview
Table 49. Roche Glioblastoma Multiforme Treatment Product
Table 50. Roche Revenue in Glioblastoma Multiforme Treatment Business (2019-2024) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Merck Company Detail
Table 53. Merck Business Overview
Table 54. Merck Glioblastoma Multiforme Treatment Product
Table 55. Merck Revenue in Glioblastoma Multiforme Treatment Business (2019-2024) & (US$ Million)
Table 56. Merck Recent Development
Table 57. Teva Company Detail
Table 58. Teva Business Overview
Table 59. Teva Glioblastoma Multiforme Treatment Product
Table 60. Teva Revenue in Glioblastoma Multiforme Treatment Business (2019-2024) & (US$ Million)
Table 61. Teva Recent Development
Table 62. AbbVie, Inc Company Detail
Table 63. AbbVie, Inc Business Overview
Table 64. AbbVie, Inc Glioblastoma Multiforme Treatment Product
Table 65. AbbVie, Inc Revenue in Glioblastoma Multiforme Treatment Business (2019-2024) & (US$ Million)
Table 66. AbbVie, Inc Recent Development
Table 67. Bristol-Myers Squibb Company Detail
Table 68. Bristol-Myers Squibb Business Overview
Table 69. Bristol-Myers Squibb Glioblastoma Multiforme Treatment Product
Table 70. Bristol-Myers Squibb Revenue in Glioblastoma Multiforme Treatment Business (2019-2024) & (US$ Million)
Table 71. Bristol-Myers Squibb Recent Development
Table 72. Sun Pharmaceutical Company Detail
Table 73. Sun Pharmaceutical Business Overview
Table 74. Sun Pharmaceutical Glioblastoma Multiforme Treatment Product
Table 75. Sun Pharmaceutical Revenue in Glioblastoma Multiforme Treatment Business (2019-2024) & (US$ Million)
Table 76. Sun Pharmaceutical Recent Development
Table 77. Arbor Pharmaceuticals Company Detail
Table 78. Arbor Pharmaceuticals Business Overview
Table 79. Arbor Pharmaceuticals Glioblastoma Multiforme Treatment Product
Table 80. Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme Treatment Business (2019-2024) & (US$ Million)
Table 81. Arbor Pharmaceuticals Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glioblastoma Multiforme Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Glioblastoma Multiforme Treatment Market Share by Type: 2023 VS 2030
Figure 3. Bevacizumab (Avastin) Features
Figure 4. Carmustine (BiCNU) Features
Figure 5. Temozolomide (Temodar and Temodal and Temcad) Features
Figure 6. Global Glioblastoma Multiforme Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Glioblastoma Multiforme Treatment Market Share by Application: 2023 VS 2030
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Glioblastoma Multiforme Treatment Report Years Considered
Figure 12. Global Glioblastoma Multiforme Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Glioblastoma Multiforme Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Glioblastoma Multiforme Treatment Market Share by Region: 2023 VS 2030
Figure 15. Global Glioblastoma Multiforme Treatment Market Share by Players in 2023
Figure 16. Global Top Glioblastoma Multiforme Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glioblastoma Multiforme Treatment as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Glioblastoma Multiforme Treatment Revenue in 2023
Figure 18. North America Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Glioblastoma Multiforme Treatment Market Share by Country (2019-2030)
Figure 20. United States Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Glioblastoma Multiforme Treatment Market Share by Country (2019-2030)
Figure 24. Germany Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Glioblastoma Multiforme Treatment Market Share by Region (2019-2030)
Figure 32. China Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Glioblastoma Multiforme Treatment Market Share by Country (2019-2030)
Figure 40. Mexico Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Glioblastoma Multiforme Treatment Market Share by Country (2019-2030)
Figure 44. Turkey Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Glioblastoma Multiforme Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Roche Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2019-2024)
Figure 47. Merck Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2019-2024)
Figure 48. Teva Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2019-2024)
Figure 49. AbbVie, Inc Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2019-2024)
Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2019-2024)
Figure 51. Sun Pharmaceutical Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2019-2024)
Figure 52. Arbor Pharmaceuticals Revenue Growth Rate in Glioblastoma Multiforme Treatment Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
